Drug Search Results
More Filters [+]

BE-1116

Alternative Names: be-1116, be1116, be 1116
Latest Update: 2024-11-01
Latest Update Note: Clinical Trial Update

Product Description

a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02281201)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CSL Behring
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BE-1116

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Injuries/wounds Unspecified|Blood Coagulation Disorders|Hemostatic Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TAP Study

P3

Terminated

Injuries/wounds Unspecified

2024-10-29

BE1116_3004

P3

Completed

Blood Coagulation Disorders|Hemostatic Disorders

2016-01-01

2005-000382-19

P3

Completed

Injuries/wounds Unspecified

2006-11-08

Recent News Events

Date

Type

Title